SNDX logo

Syndax Pharmaceuticals Inc. (SNDX)

$9.20

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SNDX

Market cap

$827901992

EPS

-2.36

P/E ratio

--

Price to sales

6.01

Dividend yield

--

Beta

0.477947

Price on SNDX

Previous close

$9.13

Today's open

$9.13

Day's range

$9.02 - $9.49

52 week range

$9.02 - $25.59

Profile about SNDX

CEO

Michael A. Metzger

Employees

298

Headquarters

New York, NY

Exchange

Nasdaq Global Select

Shares outstanding

89989347

Issue type

Common Stock

SNDX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on SNDX

Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Biopharma Conference 2026 Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Nov 12, 2026

news preview

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in connection with the hiring, announced on November 2, 2026, of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026, Mr. Ondrey received an inducement award to purchase up to 270,000 shares of common stock. The stock option has an exercise price per share of $9.55, the closing price of the Company's common stock on the Nasdaq Global Select Market on November 9, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to Mr. Ondrey's continued service relationship with Syndax through the applicable vesting dates. Syndax's Board of Directors approved the award as inducement material to Mr. Ondrey's employment in accordance with NASDAQ Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Nov 9, 2026

news preview

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax's scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia subtypes and settings, including frontline, post-transplant maintenance, and MRD relapse – – Real-world data showcase compelling results in R/R NPM1m or KMT2Ar acute leukemia patients who received revumenib monotherapy or combination therapy –  – 5 accepted axatilimab abstracts, including long-term data that highlight the potential for prolonged clinical benefit with axatilimab in R/R cGVHD – – Company to host investor event and webcast on Monday, December 14, 2026, at 7:00 a.m. CT/8:00 a.m.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 4, 2026, the Company granted inducement awards to purchase up to 213,500 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 14, 2026, from 7:00–8:30 a.m. CT / 8:00–9:30 a.m.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key

Syndax Pharmaceuticals remains on track, with Revuforj driving robust commercial growth and Niktimvo providing a secondary revenue stream. 3Q26 revenue surged 82% YoY to $83.3M, led by Revuforj's 90% YoY growth; operating losses narrowed despite rising R&D spend. Post-transplant maintenance trends could extend Revuforj treatment duration, offering upside if patient resumption rates increase, as management anticipates.

news source

Seeking Alpha • Nov 4, 2026

news preview

What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call

Syndax Pharmaceuticals NASDAQ: SNDX reported third-quarter 2026 total revenue of $83.3 million, an 82% increase from the prior-year period, as sales of its Revuforj leukemia treatment and collaboration revenue from Niktimvo continued to rise.

news source

MarketBeat • Nov 3, 2026

news preview

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026.

news source

GlobeNewsWire • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Syndax Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Syndax Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SNDX on M1